Gabapentin Tablet, Film Coated
Product Images NDC 71335-2719

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Creatinine Clearance (Gabapentin Fig1)

An illustration showing the formula for calculating Creatinine Clearance (CLCr), which includes variables for age, weight, serum creatinine, and a factor adjustment for female patients.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8; the y-axis represents mean pain scores from 0 to 10. Two dosing periods are indicated: a 4-week dose titration period followed by a 4-week fixed dose period. The graph shows a gradual decrease in pain scores for the Gabapentin group, while placebo scores remain relatively stable.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig3)

A line graph depicting weekly mean pain scores over 7 weeks from Study 2, comparing placebo with Gabapentin at 1800 mg/day and 2400 mg/day. The x-axis represents time in weeks with distinct 3-week dose titration and 4-week fixed dose periods; the y-axis shows mean pain scores ranging from 0 to 10. Three lines represent placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day pain score trends.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig4)

A bar graph titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the percentage of responders between placebo (PBO) and various dosages of Gabapentin (GBP) across two studies, showing higher response rates for Gabapentin groups ranging from 29% to 34%, versus 12% to 14% for placebo.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot showing the responder rate difference (%) versus daily dose (mg) of Gabapentin in patients aged 12 years and older with partial seizures. The graph compares data from three studies labeled a, b, and c, with daily doses ranging from 600 mg to 1800 mg and responder rate differences between approximately 2% and 20%.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure diagram of the active ingredient gabapentin, showing its molecular arrangement with a cyclohexane ring attached to amino (CH2NH2) and carboxymethyl (CH2CO2H) groups.*

FDA Label Image

Label (Lbl713352719)

Gabapentin Tablets, USP 600 mg, film-coated oral tablets, repackaged by Bryant Ranch Prepack and manufactured by Aurobindo Pharma Limited. The label includes storage instructions (20° to 25°C), child-resistant container notice, package quantity of 90 tablets, and QR codes for additional information. NDC 71335-2719-1 is displayed prominently.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.